By Josh Beckerman
Shares of G1 Therapeutics fell 46% to $2.44 in after-hours trading on Monday after the company provided an update to its Phase 3 trilaciclib combination trial.
The independent Data Monitoring Committee recommended continuation of the trial evaluating trilaciclib in combination with gemcitabine and carboplatin for first line treatment of metastatic triple negative breast cancer to the final analysis. The final analysis is estimated to occur in the third quarter.
G1 said it remains blind to all data since early stopping criteria wasn’t met during the interim analysis.
“While a positive interim analysis would have enabled us to bring this therapy to patients in need sooner, we look forward to completing the study and potentially making this meaningful new treatment option available to patients with this highly aggressive form of breast cancer as early as next year,” the company said.
The committee didn’t express any concerns regarding safety or recommend any other changes to the study, the company said.
The drug, also known as Cosela, launched in 2021. The Food and Drug Administration approved it as a therapy to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy treatment.
Write to Josh Beckerman at [email protected]
Read the full article here
